R932333 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lupus Erythematosus, Discoid
Conditions
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Trial Timeline
Aug 1, 2012 → Sep 1, 2013
NCT ID
NCT01597050About R932333 + Placebo
R932333 + Placebo is a phase 2 stage product being developed by Rigel Pharmaceuticals for Lupus Erythematosus, Discoid. The current trial status is completed. This product is registered under clinical trial identifier NCT01597050. Target conditions include Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01597050 | Phase 2 | Completed |
Competing Products
20 competing products in Lupus Erythematosus, Discoid